Home > The Group > BMJ media centre > Latest News > Antiviral therapy may halve risk of liver cancer after chronic hepatitis C infection

Antiviral therapy may halve risk of liver cancer after chronic hepatitis C infection

And has an impact even in those with more moderate response to treatment

[Antiviral therapy for prevention of hepatocellular carcinoma in chronic hepatitis C: systematic review and meta-analysis of randomised controlled trials doi 10.1136/bmjopen-2012-001313]

Treating chronic hepatitis C infection with antiviral drugs could halve the risk of developing the most common form of liver cancer, in some cases, indicates an analysis of the published research in one of the new BMJ Open Editions.*

Hepatocellular carcinoma is the most common form of liver cancer worldwide, accounting for 90 per cent of all primary cases of the disease. Cirrhosis of the liver and hepatitis C infection are among the most important risk factors.

The authors reviewed the published evidence on the use of antiviral therapy—interferon or pegylated interferon, or ribavirin, or a combination—in people with chronic hepatitis C infection, to assess its impact, and to see if the level of viral clearance, prompted by the treatment, made any difference.

In some people, antiviral treatment helps the body clear the virus; in others an initial response is followed by a relapse a few months later.  If treatment succeeds in keeping the virus at bay for six months, the chances of relapse are miniscule.

The authors reviewed the data from 8 comparative treatment trials of those whose hepatitis C infection had resulted in chronic inflammation and fibrosis (gristle) or cirrhosis (scarring and limited working capacity) of the liver.

And they also included data from five prospective cohort studies, which regularly monitor similar groups of people over the long term to see what happens to them.

In all, more than 3200 people were included in the analysis. Their treatment, which was predominantly interferon, lasted between 6 months and a year, and they were monitored for periods of between five and eight years.

In the trials, a total of 1156 people were treated with antiviral therapy, 81 of whom developed liver cancer; and 1174 were not, 129 of whom developed the disease—equivalent to a reduction in risk of 47 per cent.

Those in whom treatment cleared the virus, long term, were 85 per cent less likely to develop liver cancer compared with those in whom treatment was less effective. Nevertheless this group were still 43 per cent less likely to develop liver cancer.

The observational (cohort) study data also showed that antiviral therapy curbed the risk of liver cancer by around 70 per cent compared with those not given the treatment.

The authors caution that the length of monitoring and the lack of information on death rates could mean that treatment with interferon may simply delay, rather than prevent, liver cancer in infected patients.

But they point out that standard treatment now consists of interferon plus ribavirin, which is deemed more effective, and that the infection tends to be picked up earlier before it has had time to do wreak long term damage.

http://bit.ly/S07ei3

Press Office
Contacts
BMJ enquiries
Email Emma Dickinson
+44 (0) 20 7383 6529

BMJ Journals enquiries
Email Caroline White
+44 (0) 798 0800 465
BMJ News Channel
BMJ Affinity
Best Practice